ARCHIVES

ODAC Member Critical Of Amgen For Price Incentives.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

Drug Development: Herceptin Associated with 15 Deaths, Genentech Says

May 12, 2000

NIH Slow To Implement Equality In Studies, GAO Says, But Waxman Assures Reauthorization

June 22, 1990

Phase II ThermoDox Trial Demonstrates Positive Response

August 29, 2014

In Brief: Two Major Appointments Made At Fox Chase; HHS Names Task Force to Look At DRG Research Impact

April 20, 1984

In Brief: Lepovetsky Heads New NCI Office Of Technology Development; Temporary Now, Maybe Permanent

November 27, 1987

Accelerated Approval Will No Longer Block Competitors, FDA Commissioner Says

June 6, 2003